By Chris Wack
Autonomix Medical shares were up 39% to $14.20 after the company said it saw positive results from a clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves to mitigate pain in patients with pancreatic cancer.
The medical device company said the first 15 patients in its ongoing proof-of-concept human clinical trial saw significant reduction in pain and improvement in regards to their pancreatic cancer pain.
Autonomix said it remains on track to complete enrollment by calendar year end.
Through seven days, the post-procedure showed a decrease in opioid demand, with no responding patient needing a dose increase. No responding patient needed opioids after their 24-hour post-procedure follow-up visit.
A total of twenty patients will be enrolled in the trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 31, 2024 09:54 ET (13:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。